Post-doctoral Fellow - Clinical Vaccine Studies
Position Summary and Key Responsibilities:
The Division of Experimental Therapeutics at the Beckman Research Institute has an exciting opportunity for a motivated post doctoral scientist with an interest in immuno monitoring in clinical vaccine studies. The successful candidate will join a team committed to the ongoing multisite clinical trials to assess the efficacy of CMVPepVax (NCT#02396134) and CMV-MVA-Triplex (NCT#0250693), two experimental vaccines for cytomegalovirus (CMV), which have been both developed at City of Hope. CMV is the leading infectious complication in patients who have undergone hematopoietic stem-cell transplantation (HCT), for the treatment of blood cancers. CMVPepVax is a T-cell peptide epitope based vaccine that has shown to be well-tolerated and boosts protective immunity against CMV in HCT recipients (Nakamura et al. 2015, Lancet Haematology). CMV-MVA-Triplex is a recombinant vector vaccine expressing multiple CMV antigens, which has shown marked safety and immunogenicity in healthy adults (Diamond et al. 2015, Blood), and is being currently evaluated in HCT patients. The position will be jointly mentored by Corinna La Rosa, PhD and Don J. Diamond, PhD. It will be responsibility of the candidate to conduct immuno monitoring of patients enrolled in ongoing clinical trials. Flow cytometry, and in vitro immunoassays on peripheral blood mononuclear cells (PBMC) will be used to analyze patient response to the vaccine.
Send CV, summary of research experience/interests and contact information for three references to Peter Kwon, MPA, email@example.com.
Minimum Education and Skills Required for Consideration:
- Recent graduates with a doctoral degree or doctoral students who have achieved advancement-to-candidacy should have a strong background in cellular immunology, with documented experience in performing immuno assays with human PBMC. Experience in primary cell culture, multi color flow cytometry compensation and data analysis softwares, and measuring antigen-specific cellular immunity is preferred.
About City of Hope
City of Hope, an innovative biomedical research, treatment and educational institution with over 4000 employees, is dedicated to the prevention and cure of cancer and other life-threatening diseases and guided by a compassionate, patient-centered philosophy. Founded in 1913 and headquartered in Duarte, California, City of Hope is a remarkable non-profit institution, where compassion and advanced care go hand-in-hand with excellence in clinical and scientific research. City of Hope is a National Cancer Institute designated Comprehensive Cancer Center and a founding member of the National Comprehensive Cancer Network, an alliance of the nation’s 20 leading cancer centers that develops and institutes standards of care for cancer treatment.
City of Hope is an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, religion, color national origin, sex, age, status as a protected veteran, or status as a qualified individual with disability.